Aptose Biosciences Inc. (APTO) generated $0.00 in operating cash flow for fiscal year 2025. After capital expenditures of $0.00, free cash flow was $0.00.
Criteria supported by this page:
HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
Overall SharesGrow Score: 43/100 with 2/7 criteria passed.
